Isotretinoin: The Near-Cure With a Monitoring Burden

The four drivers of acne — and one drug for all of them

Acne is not one problem but four, tangled together in the same pore. A comedone forms when four things go wrong at once. First, the sebaceous gland pumps out too much oil (sebum), driven largely by androgens. Second, the lining of the follicle sheds its cells abnormally and they stick together, plugging the opening — abnormal keratinisation. Third, a resident bacterium, Cutibacterium acnes (formerly Propionibacterium acnes), thrives in the oily, blocked follicle. Fourth, all of this ignites inflammation, which is what turns a quiet blackhead into an angry nodule. Every other acne treatment targets one or two of these. A topical retinoid works on keratinisation; benzoyl peroxide and antibiotics on C. acnes and inflammation; hormonal therapy on sebum. Isotretinoin is unique because it strikes all four — and it is the only agent that does so by acting on the gland itself.

How one molecule shrinks the oil gland

Isotretinoin is 13-cis-retinoic acid — a vitamin A derivative, a retinoid. Like all retinoids it enters the cell and reaches nuclear retinoic-acid receptors that regulate how skin cells grow, mature and die. But its defining effect is on the sebaceous gland: it drives the oil-producing cells (sebocytes) into involution, so the gland physically shrinks and sebum output collapses — often by the majority. Strip away the oil and you pull the rug from under C. acnes, which needs that lipid-rich environment; the bacterial load falls even though isotretinoin is not an antibiotic. Retinoid signalling also normalises the abnormal keratinisation, so the follicle stops plugging itself. And with less oil, fewer bacteria and an unblocked pore, the inflammatory fire has nothing left to feed it. One mechanism — sebaceous gland involution — cascades into all four pathways at once. This retinoid receptor biology links directly to the Principles of Pharmacology chapter on nuclear hormone receptors, the same family that thyroid hormone and steroids act through.

Why it's reserved, not first-line

If isotretinoin is so effective, why not give it to everyone with a few spots? Because its power comes bundled with a burden of risk and monitoring that mild acne simply does not justify. Guidelines reserve it for severe acne — nodulocystic or scarring disease — and for moderate acne that has failed adequate courses of conventional therapy, including topical retinoids and oral antibiotics, or that relapses quickly. It is also the right early choice when acne is causing significant psychological distress, since scarring, both of skin and of confidence, is permanent. The decision is a genuine trade-off: a near-curative result weighed against teratogenicity, mucocutaneous misery and a schedule of blood tests. The judgement of when the disease is bad enough to earn the drug is the essence of good prescribing.

The defining risk: teratogenicity

No adverse effect shapes how this drug is prescribed more than what it does to a pregnancy. Isotretinoin is one of the most powerful human teratogens in medicine. Exposure in early pregnancy causes a devastating pattern of malformations — of the brain and skull, the heart and great vessels, the ears, and the face — and a high rate of miscarriage. There is no safe dose in pregnancy; even a short exposure can cause harm. Because of this, isotretinoin can only be prescribed to anyone who could become pregnant under a formal pregnancy-prevention programme (in the United States this is iPLEDGE; equivalent programmes exist elsewhere). The core requirements are consistent: reliable contraception — typically two methods used together — beginning before treatment and continuing for a defined interval after it stops; pregnancy tests before starting, monthly during treatment, and after finishing; and prescriptions limited to short intervals so testing is never skipped. Reassuringly, the drug clears the body quickly, so the risk ends soon after the course does — but the discipline in between is absolute. This is the clinical face of the teratogenicity principle taught in Principles of Pharmacology, where the same logic governs warfarin, valproate and the ACE inhibitors.

The everyday toxicity: everything dries out

Shut down oil production across the whole body and the predictable consequence is dryness everywhere a mucous membrane or an oil gland used to keep things moist. The near-universal effect is cheilitis — cracked, chapped, sometimes bleeding lips — so consistent that its presence is almost a marker the patient is actually taking the drug. Add dry, easily irritated skin; dry eyes (troublesome for contact-lens wearers); a dry nose that gives nosebleeds (epistaxis); and heightened photosensitivity, so the skin burns more readily and sun protection is not optional. Many patients also report muscle and joint aches (myalgia and arthralgia), especially if they exercise hard. None of these is dangerous on its own, but together they define the lived experience of a course, and honest counselling about them is what keeps a patient adherent long enough to reach the cumulative dose.

What the blood tests are watching

Beyond pregnancy testing, isotretinoin carries two laboratory concerns that drive routine monitoring. It commonly raises blood lipids — triglycerides especially, and cholesterol — occasionally to levels that matter, so a lipid panel is checked before and during treatment. It can also raise liver enzymes (transaminases), so liver function tests (LFTs) are monitored alongside. In most patients these shifts are mild and reversible, managed by dose adjustment or, rarely, stopping; but they are the reason the drug is never a fire-and-forget prescription. This routine sits inside the broader framework taught in "When Dermatology Goes Systemic" — the discipline of baseline-then-interval blood monitoring that every systemic dermatology drug demands, from methotrexate to the biologics.

Mood, interactions, and the initial flare

Three more things every prescriber must raise before the first capsule. First, mood. A possible association between isotretinoin and depression, mood change and, rarely, suicidal thinking has been debated for years; the causal link remains unproven and severe acne itself harms mental health, but the responsible position is the same either way — counsel the patient and their family about what to watch for, and monitor mood at every visit. Second, drug interactions worth memorising. Never combine isotretinoin with a tetracycline antibiotic (doxycycline, minocycline): both independently raise intracranial pressure, and together they can cause idiopathic intracranial hypertension — headache, visual disturbance, papilloedema. This is exactly why the antibiotic step in the Antimicrobials chapter must be stopped before isotretinoin begins. And avoid supplemental vitamin A, since isotretinoin is a vitamin A derivative and stacking them risks additive hypervitaminosis-A toxicity. Third, warn that acne often flares in the first weeks before it improves — an expected initial worsening, not a treatment failure, and a moment when clear counselling keeps a frightened patient from quitting too soon.